WINT Windtree Therapeutics, Inc. Stock Quote

WINT [NASD]

Index	-	P/E	-	EPS (ttm)	-2.29	Insider Own	0.50%	Shs Outstand	16.58M	Perf Week	-17.78%
Market Cap	72.44M	Forward P/E	-	EPS next Y	-1.84	Insider Trans	4.04%	Shs Float	4.47M	Perf Month	-21.51%
Income	-32.50M	PEG	-	EPS next Q	-0.45	Inst Own	4.00%	Short Float	1.91%	Perf Quarter	-33.97%
Sales	0.00M	P/S	-	EPS this Y	89.20%	Inst Trans	-8.22%	Short Ratio	1.95	Perf Half Y	-47.83%
Book/sh	4.57	P/B	0.95	EPS next Y	12.40%	ROA	-27.10%	Target Price	-	Perf Year	-65.67%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-42.70%	52W Range	4.00 - 12.00	Perf YTD	-15.69%
Dividend	-	P/FCF	-	EPS past 5Y	64.30%	ROI	-28.20%	52W High	-63.96%	Beta	-0.08
Dividend %	-	Quick Ratio	3.80	Sales past 5Y	-41.30%	Gross Margin	-	52W Low	8.12%	ATR	0.34
Employees	31	Current Ratio	3.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	21.18	Volatility	9.04% 5.39%
Optionable	No	Debt/Eq	0.24	EPS Q/Q	18.10%	Profit Margin	-	Rel Volume	3.50	Prev Close	4.94
Shortable	Yes	LT Debt/Eq	0.23	Earnings	-	Payout	-	Avg Volume	43.84K	Price	4.32
Recom	1.00	SMA20	-20.01%	SMA50	-21.23%	SMA200	-34.87%	Volume	153,389	Change	-12.45%

Jun-26-20

Initiated

Ladenburg Thalmann

Buy

$12.25

Feb-22-21 08:18AM	WINT: Recent News Updates Positive For Lead Assets and Programs Zacks Small Cap Research
Feb-16-21 07:00AM	Windtree Announces Issuance of New U.S. Patent Covering Technology on Its Redesigned AEROSURF® Device PR Newswire
Feb-04-21 08:30AM	Windtree Strengthens Its Board by Appointing Three New Directors PR Newswire
Feb-01-21 04:30PM	Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development PR Newswire
Jan-06-21 08:00AM	Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19 PR Newswire
Nov-24-20 06:15AM	WINT: Clinical Studies Moving Forward For Both Lead Treatment Programs Zacks Small Cap Research
Nov-16-20 07:45AM	Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates PR Newswire
Oct-01-20 07:30AM	Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients PR Newswire
Sep-29-20 07:30AM	Windtree Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19 PR Newswire
Sep-08-20 08:00AM	Windtree to Present at H.C. Wainwright 22nd Annual Global Investment Conference PR Newswire +18.64%
Aug-31-20 12:06PM	WINT: Advancing Two Lead Fast Track-Designated Drug Candidates Toward Approval & Commercialization Zacks Small Cap Research -7.12%
Aug-13-20 07:36PM	Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates GlobeNewswire
Jul-21-20 07:00AM	Windtree Adds to Team with Appointment of Three Industry Veterans PR Newswire
Jul-20-20 07:00AM	Windtree Appoints John Hamill as Chief Financial Officer PR Newswire
Jun-30-20 08:43AM	Did Windtree Therapeutics, Inc. (NASDAQ:WINT) Insiders Buy Up More Shares? Simply Wall St.
Jun-24-20 08:00AM	Windtree Announces Initial European Trial Sites Activated in AEROSURF® Bridging Study and a Collaboration for a Concomitant Independent Cerebral Physiology Study PR Newswire
May-28-20 08:00AM	Windtree to Host Company and Business Update Conference Call on June 4, 2020 PR Newswire
May-22-20 04:05PM	Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option PR Newswire
May-20-20 08:30AM	Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market PR Newswire -14.55%
May-14-20 08:00AM	Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates PR Newswire
Apr-29-20 07:45AM	Windtree Announces First Patient Enrolled in AEROSURF® Bridging Study for the Treatment of Respiratory Distress Syndrome PR Newswire
Apr-28-20 04:05PM	Windtree Therapeutics Announces Reverse Stock Split PR Newswire +8.20%
Apr-06-20 07:45AM	Windtree Presents New Istaroxime Phase 2b Study Analysis at the American College of Cardiology (ACC) Congress PR Newswire
Apr-02-20 07:30PM	Windtree Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Key Business Updates PR Newswire
Mar-31-20 07:45AM	Windtree Enters into Agreement with Lee's Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF® PR Newswire
Mar-24-20 07:45AM	Windtree to Pursue Clinical Study of Lung Injury Treatment in COVID-19 Patients with its KL4 Surfactant Therapy PR Newswire +59.50%
Dec-09-19 08:00AM	Windtree to Host a Conference Call on December 11, 2019 to Provide Development Programs and Financial Update PR Newswire -7.50%

Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fraser Craig	President and CEO	Oct 28	Buy	6.56	250	1,640	24,298	Oct 29 06:08 AM
Huang James	Director	Oct 23	Buy	6.67	1,000	6,666	21,000	Oct 27 06:02 AM
Fraser Craig	President and CEO	Oct 09	Buy	5.83	250	1,456	24,048	Oct 13 08:40 AM
Curtis Eric	SVP & COO	Oct 08	Buy	5.27	500	2,635	500	Oct 09 08:03 AM
Hamill John P.	SVP & CFO	Oct 07	Buy	5.27	1,000	5,270	1,000	Oct 09 08:06 AM
Fraser Craig	President and CEO	Oct 07	Buy	5.17	250	1,293	23,798	Oct 09 08:05 AM
Huang James	Director	Jun 04	Buy	7.32	12,200	89,332	20,200	Jun 05 08:36 PM
Huang James	Director	Jun 03	Buy	7.42	200	1,484	8,000	Jun 05 08:36 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience